High Pressure Homogenisation & the next generation of drug delivery: Liposomes
24 February 2016 | By Biopharma Group
Liposomes are valued delivery vehicles for potent and efficacious active pharmaceuticals...
List view / Grid view
News
CPhI Russia 2016 opens as the country is seeking rapid upgrades to GMP standards
24 February 2016 | By CPhI
CPhI Russia @ IPhEB, organised by UBM EMEA, returns for the fourth consecutive year in Russia as business opportunities in the country remain diverse...
Once-daily Isentress formulation meets endpoints in Phase III trial
23 February 2016 | By Victoria White
ONCEMRK is evaluating an investigational once-daily formulation of Isentress (raltegravir), known as raltegravir 600 mg, for previously untreated HIV-1 infected adults...
L.B. Bohle increases turnover to EUR 48 million – Pharmaceutical industry makes use of Technology Center
23 February 2016 | By L.B. Bohle Maschinen + Verfahren GmbH
The investments in the future have paid off for L.B. Bohle Maschinen + Verfahren GmbH in the 2015 business year...
FDA approves expanded indication for Pfizer’s Ibrance
23 February 2016 | By Victoria White
Ibrance is approved for the treatment of HR+, HER2- advanced or metastatic breast cancer in combination with fulvestrant in women with disease progression following endocrine therapy...
Positive top-line results for romosozumab FRAME study
23 February 2016 | By Victoria White
The Phase III FRAME study evaluated UCB and Amgen's romosozumab in postmenopausal women with osteoporosis...
FDA accepts NDA for Sanofi’s combination of insulin glargine and lixisenatide
23 February 2016 | By Victoria White
This NDA submission is based on data from two Phase 3 studies of insulin glargine and lixisenatide in patients with with type 2 diabetes...
New brochure from Copley Scientific delivers essential information on its upgraded pharmaceutical testing range
22 February 2016 | By Copley Scientific
The latest version of ‘Quality Solutions for the Testing of Pharmaceuticals’ from Copley Scientific provides detailed information for those seeking assistance with the interpretation and application of regulatory guidance, as well as highlighting new additions to the company’s extensive range...
Preserving blood – why we need to look at new options
Blood transfusions have been used successfully since the early 1900s, and blood banks have been in use since 1914. After donation, whole blood is separated into several components for processing and storage under different conditions, and one of these components is the red blood cell fraction.
How the use of placebos in freeze-drying enables cost efficiencies in process & cycle development
A placebo is a simulated or otherwise medically ineffectual treatment for a disease or other medical condition intended to make the recipient believe they are receiving something they are not in order to establish whether the true active agent has a noticeable remedy to the ailment it is intended to…
EC approves AstraZeneca’s Brilique at a new 60mg dose
19 February 2016 | By Victoria White
After the first year, patients with a history of heart attack can now continue to be treated with Brilique at the lower dose of 60mg twice daily...
Many clinical trial results not shared, finds study
19 February 2016 | By Victoria White
According to a new study, less than 40% of the results of clinical trials conducted at leading academic medical centres were shared within two years of completion...
AstraZeneca’s Zurampic approved in the EU for patients with gout
19 February 2016 | By Victoria White
In combination with the current standard of care, Zurampic provides a dual mechanism of action to increase excretion and decrease production of uric acid...
FDA grants Breakthrough Therapy status to PKC412 (midostaurin)
19 February 2016 | By Victoria White
PKC412 (midostaurin) is an investigational treatment for adults with newly-diagnosed acute myeloid leukaemia who are FLT3 mutation-positive...
Acelity partners with Mediq to strengthen its offering in Europe
19 February 2016 | By Victoria White
Acelity has announced a partnership with Mediq to exclusively distribute Acelity’s advanced wound care and regenerative medicine portfolio in Denmark, Finland, Norway and Sweden.
